
Supplementary figure S1 a) IRs (95% CI) and b) HRs^a (95% CI) between treatment groups, overall and stratified by age (<65 years or \geq 65 years), and c) HRs^b (95% CI) between age groups for each treatment group, for all infection events (non-serious and serious) in pooled Phase 2, 3 and 3b/4 studies (Months 0–12).^c



Pooled data from Phase 2 (A3921035; NCT00550446), Phase 3 (ORAL Standard; NCT00853385) and Phase 3b/4 (ORAL Strategy; NCT02187055) studies

IR=unique patients with events/100 PY


^aCox proportional hazards model includes treatment as the only factor


^bCox proportional hazards model includes treatment, age group (<65 years or \geq 65 years) and treatment by age group interaction terms

^cFor Study A3921035, only data within the first 3-month randomised parallel treatment period were included (before patients who were receiving ADA were switched to tofacitinib 5 mg BID after Month 3)

ADA, adalimumab; BID, twice daily; CI, confidence interval; HR, hazard ratio; IR, incidence rate; N, number of treated patients; n, number of patients with event; PY, patient-years

Supplementary figure S2 IRs (95% CI) of SIEs in the US Corrona RA registry, stratified by





Data from the US Corrona RA registry for patients initiating tofacitinib or bDMARDs between 6 November 2012 and 31 January 2019

Age-/gender-adjusted IR=first events/100 PY

bDMARD, biologic disease-modifying antirheumatic drug; CI, confidence interval; IR, incidence rate; N, number of patients in each treatment group; n, number of patients with event; PY, patient-years; RA, rheumatoid arthritis; SIE, serious infection event